FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-12

AUTHORS

Lana McClements, Stephanie Annett, Anita Yakkundi, Martin O'Rourke, Andrea Valentine, Nermeen Moustafa, Abdelrahim Alqudah, Bruno M Simões, Fiona Furlong, Amy Short, Stuart A McIntosh, Helen O McCarthy, Robert B Clarke, Tracy Robson

ABSTRACT

BACKGROUND: Optimising breast cancer treatment remains a challenge. Resistance to therapy is a major problem in both ER- and ER+ breast cancer. Tumour recurrence after chemotherapy and/or targeted therapy leads to more aggressive tumours with enhanced metastatic ability. Self-renewing cancer stem cells (CSCs) have been implicated in treatment resistance, recurrence and the development of metastatic disease. METHODS: In this study, we utilised in vitro, in vivo and ex vivo breast cancer models using ER+ MCF-7 and ER- MDA-MB-231 cells, as well as solid and metastatic breast cancer patient samples, to interrogate the effects of FKBPL and its peptide therapeutics on metastasis, endocrine therapy resistant CSCs and DLL4 and Notch4 expression. The effects of FKBPL overexpression or peptide treatment were assessed using a t-test or one-way ANOVA with Dunnett's multiple comparison test. RESULTS: We demonstrated that FKBPL overexpression or treatment with FKBPL-based therapeutics (AD-01, pre-clinical peptide /ALM201, clinical peptide) inhibit i) CSCs in both ER+ and ER- breast cancer, ii) cancer metastasis in a triple negative breast cancer metastasis model and iii) endocrine therapy resistant CSCs in ER+ breast cancer, via modulation of the DLL4 and Notch4 protein and/or mRNA expression. AD-01 was effective at reducing triple negative MDA-MB-231 breast cancer cell migration (n ≥ 3, p < 0.05) and invasion (n ≥ 3, p < 0.001) and this was translated in vivo where AD-01 inhibited breast cancer metastasis in MDA-MB-231-lucD3H1 in vivo model (p < 0.05). In ER+ MCF-7 cells and primary breast tumour samples, we demonstrated that ALM201 inhibits endocrine therapy resistant mammospheres, representative of CSC content (n ≥ 3, p < 0.05). Whilst an in vivo limiting dilution assay, using SCID mice, demonstrated that ALM201 alone or in combination with tamoxifen was very effective at delaying tumour recurrence by 12 (p < 0.05) or 21 days (p < 0.001), respectively, by reducing the number of CSCs. The potential mechanism of action, in addition to CD44, involves downregulation of DLL4 and Notch4. CONCLUSION: This study demonstrates, for the first time, the pre-clinical activity of novel systemic anti-cancer therapeutic peptides, ALM201 and AD-01, in the metastatic setting, and highlights their impact on endocrine therapy resistant CSCs; both areas of unmet clinical need. More... »

PAGES

351

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12885-019-5500-0

DOI

http://dx.doi.org/10.1186/s12885-019-5500-0

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1113377817

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30975104


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Technology Sydney", 
          "id": "https://www.grid.ac/institutes/grid.117476.2", 
          "name": [
            "Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK.", 
            "School of Pharmacy, Queen's University Belfast, Belfast, UK.", 
            "The School of Life Sciences, University of Technology Sydney, Sydney, Australia."
          ], 
          "type": "Organization"
        }, 
        "familyName": "McClements", 
        "givenName": "Lana", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Royal College of Surgeons in Ireland", 
          "id": "https://www.grid.ac/institutes/grid.4912.e", 
          "name": [
            "School of Pharmacy, Queen's University Belfast, Belfast, UK.", 
            "Department of Molecular and Cellular Therapeutics, Irish Centre for Vascular Biology, Royal College of Surgeons in Ireland, RCSI, Dublin, Ireland."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Annett", 
        "givenName": "Stephanie", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Queen's University Belfast", 
          "id": "https://www.grid.ac/institutes/grid.4777.3", 
          "name": [
            "School of Pharmacy, Queen's University Belfast, Belfast, UK."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yakkundi", 
        "givenName": "Anita", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Queen's University Belfast", 
          "id": "https://www.grid.ac/institutes/grid.4777.3", 
          "name": [
            "School of Pharmacy, Queen's University Belfast, Belfast, UK.", 
            "Charles River Labs, 8-9 Spire Green Centre, Essex, Harlow, CM19 5TR, UK."
          ], 
          "type": "Organization"
        }, 
        "familyName": "O'Rourke", 
        "givenName": "Martin", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Queen's University Belfast", 
          "id": "https://www.grid.ac/institutes/grid.4777.3", 
          "name": [
            "School of Pharmacy, Queen's University Belfast, Belfast, UK.", 
            "Charles River Labs, 8-9 Spire Green Centre, Essex, Harlow, CM19 5TR, UK."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Valentine", 
        "givenName": "Andrea", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Queen's University Belfast", 
          "id": "https://www.grid.ac/institutes/grid.4777.3", 
          "name": [
            "School of Pharmacy, Queen's University Belfast, Belfast, UK."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Moustafa", 
        "givenName": "Nermeen", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hashemite University", 
          "id": "https://www.grid.ac/institutes/grid.33801.39", 
          "name": [
            "Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK.", 
            "School of Pharmacy, Hashemite University, Amman, Jordan."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Alqudah", 
        "givenName": "Abdelrahim", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Manchester", 
          "id": "https://www.grid.ac/institutes/grid.5379.8", 
          "name": [
            "Manchester Breast Centre, Division of Cancer Sciences, University of Manchester, Oglesby Cancer Research Building, Manchester, UK."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sim\u00f5es", 
        "givenName": "Bruno M", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Queen's University Belfast", 
          "id": "https://www.grid.ac/institutes/grid.4777.3", 
          "name": [
            "School of Pharmacy, Queen's University Belfast, Belfast, UK."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Furlong", 
        "givenName": "Fiona", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Queen's University Belfast", 
          "id": "https://www.grid.ac/institutes/grid.4777.3", 
          "name": [
            "School of Pharmacy, Queen's University Belfast, Belfast, UK."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Short", 
        "givenName": "Amy", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Belfast City Hospital", 
          "id": "https://www.grid.ac/institutes/grid.412914.b", 
          "name": [
            "Centre for Cancer Research and Cell Biology, Queen's University Belfast and Breast Surgery Department, Belfast City Hospital, Belfast, UK."
          ], 
          "type": "Organization"
        }, 
        "familyName": "McIntosh", 
        "givenName": "Stuart A", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Queen's University Belfast", 
          "id": "https://www.grid.ac/institutes/grid.4777.3", 
          "name": [
            "School of Pharmacy, Queen's University Belfast, Belfast, UK."
          ], 
          "type": "Organization"
        }, 
        "familyName": "McCarthy", 
        "givenName": "Helen O", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Manchester", 
          "id": "https://www.grid.ac/institutes/grid.5379.8", 
          "name": [
            "Manchester Breast Centre, Division of Cancer Sciences, University of Manchester, Oglesby Cancer Research Building, Manchester, UK."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Clarke", 
        "givenName": "Robert B", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Royal College of Surgeons in Ireland", 
          "id": "https://www.grid.ac/institutes/grid.4912.e", 
          "name": [
            "School of Pharmacy, Queen's University Belfast, Belfast, UK. tracyrobson@rcsi.ie.", 
            "Department of Molecular and Cellular Therapeutics, Irish Centre for Vascular Biology, Royal College of Surgeons in Ireland, RCSI, Dublin, Ireland. tracyrobson@rcsi.ie."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Robson", 
        "givenName": "Tracy", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/nature10983", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014607335", 
          "https://doi.org/10.1038/nature10983"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1371/journal.pone.0055075", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022426445"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.18632/oncotarget.3410", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049700121"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-12", 
    "datePublishedReg": "2019-12-01", 
    "description": "BACKGROUND: Optimising breast cancer treatment remains a challenge. Resistance to therapy is a major problem in both ER- and ER+ breast cancer. Tumour recurrence after chemotherapy and/or targeted therapy leads to more aggressive tumours with enhanced metastatic ability. Self-renewing cancer stem cells (CSCs) have been implicated in treatment resistance, recurrence and the development of metastatic disease.\nMETHODS: In this study, we utilised in vitro, in vivo and ex vivo breast cancer\u00a0models using ER+ MCF-7 and ER- MDA-MB-231 cells, as well as solid and metastatic breast cancer patient samples, to interrogate the effects of FKBPL and its peptide therapeutics on metastasis, endocrine therapy resistant CSCs and DLL4 and Notch4 expression. The effects of FKBPL overexpression or peptide treatment were assessed using a t-test or one-way ANOVA with Dunnett's multiple comparison test.\nRESULTS: We demonstrated that FKBPL overexpression or treatment with FKBPL-based therapeutics (AD-01, pre-clinical peptide /ALM201, clinical peptide) inhibit i) CSCs in both ER+ and ER- breast cancer, ii) cancer metastasis in a triple negative breast cancer metastasis model and iii) endocrine therapy resistant CSCs in ER+ breast cancer, via modulation of the DLL4 and Notch4 protein and/or mRNA expression. AD-01 was effective at reducing triple negative MDA-MB-231 breast cancer cell migration (n\u2009\u2265\u20093, p\u2009<\u20090.05) and invasion (n\u2009\u2265\u20093, p\u2009<\u20090.001) and this was translated in vivo where AD-01 inhibited breast cancer metastasis in MDA-MB-231-lucD3H1 in vivo model (p\u2009<\u20090.05). In ER+ MCF-7 cells and primary breast tumour samples, we demonstrated that ALM201 inhibits endocrine therapy resistant mammospheres, representative of CSC content (n\u2009\u2265\u20093, p\u2009<\u20090.05). Whilst an in vivo limiting dilution assay, using SCID mice, demonstrated that ALM201 alone or in combination with tamoxifen was very effective at delaying tumour recurrence by 12 (p\u2009<\u20090.05) or 21\u2009days (p\u2009<\u20090.001), respectively, by reducing the number of CSCs. The potential mechanism of action, in addition to CD44, involves downregulation of DLL4 and Notch4.\nCONCLUSION: This study demonstrates, for the first time, the pre-clinical activity of novel systemic anti-cancer therapeutic peptides, ALM201 and AD-01, in the metastatic setting, and highlights their impact on endocrine therapy resistant\u00a0CSCs; both areas of unmet clinical need.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s12885-019-5500-0", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1024632", 
        "issn": [
          "1471-2407"
        ], 
        "name": "BMC Cancer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "19"
      }
    ], 
    "name": "FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4.", 
    "pagination": "351", 
    "productId": [
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12885-019-5500-0"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1113377817"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "100967800"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30975104"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12885-019-5500-0", 
      "https://app.dimensions.ai/details/publication/pub.1113377817"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-16T06:25", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000377_0000000377/records_106834_00000003.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://bmccancer.biomedcentral.com/articles/10.1186/s12885-019-5500-0"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12885-019-5500-0'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12885-019-5500-0'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12885-019-5500-0'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12885-019-5500-0'


 

This table displays all metadata directly associated to this object as RDF triples.

173 TRIPLES      21 PREDICATES      31 URIs      20 LITERALS      8 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12885-019-5500-0 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author Nc0d95700a0ae4c5fbb0863e5c0564fea
4 schema:citation sg:pub.10.1038/nature10983
5 https://doi.org/10.1371/journal.pone.0055075
6 https://doi.org/10.18632/oncotarget.3410
7 schema:datePublished 2019-12
8 schema:datePublishedReg 2019-12-01
9 schema:description BACKGROUND: Optimising breast cancer treatment remains a challenge. Resistance to therapy is a major problem in both ER- and ER+ breast cancer. Tumour recurrence after chemotherapy and/or targeted therapy leads to more aggressive tumours with enhanced metastatic ability. Self-renewing cancer stem cells (CSCs) have been implicated in treatment resistance, recurrence and the development of metastatic disease. METHODS: In this study, we utilised in vitro, in vivo and ex vivo breast cancer models using ER+ MCF-7 and ER- MDA-MB-231 cells, as well as solid and metastatic breast cancer patient samples, to interrogate the effects of FKBPL and its peptide therapeutics on metastasis, endocrine therapy resistant CSCs and DLL4 and Notch4 expression. The effects of FKBPL overexpression or peptide treatment were assessed using a t-test or one-way ANOVA with Dunnett's multiple comparison test. RESULTS: We demonstrated that FKBPL overexpression or treatment with FKBPL-based therapeutics (AD-01, pre-clinical peptide /ALM201, clinical peptide) inhibit i) CSCs in both ER+ and ER- breast cancer, ii) cancer metastasis in a triple negative breast cancer metastasis model and iii) endocrine therapy resistant CSCs in ER+ breast cancer, via modulation of the DLL4 and Notch4 protein and/or mRNA expression. AD-01 was effective at reducing triple negative MDA-MB-231 breast cancer cell migration (n ≥ 3, p < 0.05) and invasion (n ≥ 3, p < 0.001) and this was translated in vivo where AD-01 inhibited breast cancer metastasis in MDA-MB-231-lucD3H1 in vivo model (p < 0.05). In ER+ MCF-7 cells and primary breast tumour samples, we demonstrated that ALM201 inhibits endocrine therapy resistant mammospheres, representative of CSC content (n ≥ 3, p < 0.05). Whilst an in vivo limiting dilution assay, using SCID mice, demonstrated that ALM201 alone or in combination with tamoxifen was very effective at delaying tumour recurrence by 12 (p < 0.05) or 21 days (p < 0.001), respectively, by reducing the number of CSCs. The potential mechanism of action, in addition to CD44, involves downregulation of DLL4 and Notch4. CONCLUSION: This study demonstrates, for the first time, the pre-clinical activity of novel systemic anti-cancer therapeutic peptides, ALM201 and AD-01, in the metastatic setting, and highlights their impact on endocrine therapy resistant CSCs; both areas of unmet clinical need.
10 schema:genre research_article
11 schema:inLanguage en
12 schema:isAccessibleForFree true
13 schema:isPartOf N00d2d35f30fd4e4d8f4d7b2d3be3e293
14 Nc0638dbc7d3e4f93ac7be87219ad3dac
15 sg:journal.1024632
16 schema:name FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4.
17 schema:pagination 351
18 schema:productId Na416fb62eb82416fba2bc771c1505329
19 Nabb43eb1c48b42fda6252d905822a93f
20 Nca451dd4de254b5fa020211b1f606a91
21 Ne0a532dfacb8462fbbb499de6c80658e
22 schema:sameAs https://app.dimensions.ai/details/publication/pub.1113377817
23 https://doi.org/10.1186/s12885-019-5500-0
24 schema:sdDatePublished 2019-04-16T06:25
25 schema:sdLicense https://scigraph.springernature.com/explorer/license/
26 schema:sdPublisher Nb4def9710cbc4863958cbfa011d21074
27 schema:url https://bmccancer.biomedcentral.com/articles/10.1186/s12885-019-5500-0
28 sgo:license sg:explorer/license/
29 sgo:sdDataset articles
30 rdf:type schema:ScholarlyArticle
31 N00d2d35f30fd4e4d8f4d7b2d3be3e293 schema:volumeNumber 19
32 rdf:type schema:PublicationVolume
33 N0c680e3f23c94727b6c1e7817585af0c schema:affiliation https://www.grid.ac/institutes/grid.4777.3
34 schema:familyName Yakkundi
35 schema:givenName Anita
36 rdf:type schema:Person
37 N15313378fbc241afacc75bd5eda406bc schema:affiliation https://www.grid.ac/institutes/grid.4777.3
38 schema:familyName McCarthy
39 schema:givenName Helen O
40 rdf:type schema:Person
41 N1ab9ab55144648cc9dbe9ed27d548eb3 schema:affiliation https://www.grid.ac/institutes/grid.5379.8
42 schema:familyName Clarke
43 schema:givenName Robert B
44 rdf:type schema:Person
45 N29fffb0b8fe74389a3aa26b96b311eb9 schema:affiliation https://www.grid.ac/institutes/grid.5379.8
46 schema:familyName Simões
47 schema:givenName Bruno M
48 rdf:type schema:Person
49 N2df3cd3aa11845229a387559c0ab1682 schema:affiliation https://www.grid.ac/institutes/grid.4777.3
50 schema:familyName Short
51 schema:givenName Amy
52 rdf:type schema:Person
53 N36107609374942b3bf75961a99573ffd rdf:first N29fffb0b8fe74389a3aa26b96b311eb9
54 rdf:rest N8809e6df04434ddd94e7b63a7aa81d3d
55 N3b2fd3e2dac4434ebe69f3829d7df788 schema:affiliation https://www.grid.ac/institutes/grid.4777.3
56 schema:familyName Valentine
57 schema:givenName Andrea
58 rdf:type schema:Person
59 N463d561decda427fb3cecef6013da64b schema:affiliation https://www.grid.ac/institutes/grid.4777.3
60 schema:familyName O'Rourke
61 schema:givenName Martin
62 rdf:type schema:Person
63 N46642c49a3db4e8a8f24362dfef6ea24 rdf:first N2df3cd3aa11845229a387559c0ab1682
64 rdf:rest Nb2df57d3188d4b068302eb6d304bbd71
65 N4c2799e79d28401185d9418bbd4d99c0 rdf:first N463d561decda427fb3cecef6013da64b
66 rdf:rest N501b901e3cb74df1972a3363c120044d
67 N501b901e3cb74df1972a3363c120044d rdf:first N3b2fd3e2dac4434ebe69f3829d7df788
68 rdf:rest N7c0cba7292244de79950d3492c6aac70
69 N70af3b3576e4458dbdf09945f8fc8c9b schema:affiliation https://www.grid.ac/institutes/grid.4912.e
70 schema:familyName Robson
71 schema:givenName Tracy
72 rdf:type schema:Person
73 N7c0cba7292244de79950d3492c6aac70 rdf:first Nc0461894a3d945728c8b49636ba9d188
74 rdf:rest Nd7f273739d99413a85fe1d90e7a381f0
75 N7c34335c845942388a52a84595588386 rdf:first N0c680e3f23c94727b6c1e7817585af0c
76 rdf:rest N4c2799e79d28401185d9418bbd4d99c0
77 N7f611c4d516f48c2a704813ce3d78f03 schema:affiliation https://www.grid.ac/institutes/grid.4777.3
78 schema:familyName Furlong
79 schema:givenName Fiona
80 rdf:type schema:Person
81 N8809e6df04434ddd94e7b63a7aa81d3d rdf:first N7f611c4d516f48c2a704813ce3d78f03
82 rdf:rest N46642c49a3db4e8a8f24362dfef6ea24
83 N8c6ffd806508480ea2cf520291d014fc rdf:first N70af3b3576e4458dbdf09945f8fc8c9b
84 rdf:rest rdf:nil
85 N93b5407459dc40e198a3f1ab6119ac8e rdf:first Nddfc537bccc94a11af5830475142b202
86 rdf:rest N7c34335c845942388a52a84595588386
87 N95f369244218425d88067bb320b678bd rdf:first N1ab9ab55144648cc9dbe9ed27d548eb3
88 rdf:rest N8c6ffd806508480ea2cf520291d014fc
89 Na416fb62eb82416fba2bc771c1505329 schema:name doi
90 schema:value 10.1186/s12885-019-5500-0
91 rdf:type schema:PropertyValue
92 Na7e72c0ab81f40099ce3e383ebf008aa schema:affiliation https://www.grid.ac/institutes/grid.412914.b
93 schema:familyName McIntosh
94 schema:givenName Stuart A
95 rdf:type schema:Person
96 Nabb43eb1c48b42fda6252d905822a93f schema:name nlm_unique_id
97 schema:value 100967800
98 rdf:type schema:PropertyValue
99 Nb2df57d3188d4b068302eb6d304bbd71 rdf:first Na7e72c0ab81f40099ce3e383ebf008aa
100 rdf:rest Nbd08a4f67eba4281a19b31c39bf3556a
101 Nb4def9710cbc4863958cbfa011d21074 schema:name Springer Nature - SN SciGraph project
102 rdf:type schema:Organization
103 Nb5883b6f7c4f47c19a9cb1c803382b7f schema:affiliation https://www.grid.ac/institutes/grid.33801.39
104 schema:familyName Alqudah
105 schema:givenName Abdelrahim
106 rdf:type schema:Person
107 Nbd08a4f67eba4281a19b31c39bf3556a rdf:first N15313378fbc241afacc75bd5eda406bc
108 rdf:rest N95f369244218425d88067bb320b678bd
109 Nc0461894a3d945728c8b49636ba9d188 schema:affiliation https://www.grid.ac/institutes/grid.4777.3
110 schema:familyName Moustafa
111 schema:givenName Nermeen
112 rdf:type schema:Person
113 Nc0638dbc7d3e4f93ac7be87219ad3dac schema:issueNumber 1
114 rdf:type schema:PublicationIssue
115 Nc0d95700a0ae4c5fbb0863e5c0564fea rdf:first Nfbc92335d24e4c26807d11f38d744440
116 rdf:rest N93b5407459dc40e198a3f1ab6119ac8e
117 Nca451dd4de254b5fa020211b1f606a91 schema:name dimensions_id
118 schema:value pub.1113377817
119 rdf:type schema:PropertyValue
120 Nd7f273739d99413a85fe1d90e7a381f0 rdf:first Nb5883b6f7c4f47c19a9cb1c803382b7f
121 rdf:rest N36107609374942b3bf75961a99573ffd
122 Nddfc537bccc94a11af5830475142b202 schema:affiliation https://www.grid.ac/institutes/grid.4912.e
123 schema:familyName Annett
124 schema:givenName Stephanie
125 rdf:type schema:Person
126 Ne0a532dfacb8462fbbb499de6c80658e schema:name pubmed_id
127 schema:value 30975104
128 rdf:type schema:PropertyValue
129 Nfbc92335d24e4c26807d11f38d744440 schema:affiliation https://www.grid.ac/institutes/grid.117476.2
130 schema:familyName McClements
131 schema:givenName Lana
132 rdf:type schema:Person
133 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
134 schema:name Medical and Health Sciences
135 rdf:type schema:DefinedTerm
136 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
137 schema:name Oncology and Carcinogenesis
138 rdf:type schema:DefinedTerm
139 sg:journal.1024632 schema:issn 1471-2407
140 schema:name BMC Cancer
141 rdf:type schema:Periodical
142 sg:pub.10.1038/nature10983 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014607335
143 https://doi.org/10.1038/nature10983
144 rdf:type schema:CreativeWork
145 https://doi.org/10.1371/journal.pone.0055075 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022426445
146 rdf:type schema:CreativeWork
147 https://doi.org/10.18632/oncotarget.3410 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049700121
148 rdf:type schema:CreativeWork
149 https://www.grid.ac/institutes/grid.117476.2 schema:alternateName University of Technology Sydney
150 schema:name Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK.
151 School of Pharmacy, Queen's University Belfast, Belfast, UK.
152 The School of Life Sciences, University of Technology Sydney, Sydney, Australia.
153 rdf:type schema:Organization
154 https://www.grid.ac/institutes/grid.33801.39 schema:alternateName Hashemite University
155 schema:name Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK.
156 School of Pharmacy, Hashemite University, Amman, Jordan.
157 rdf:type schema:Organization
158 https://www.grid.ac/institutes/grid.412914.b schema:alternateName Belfast City Hospital
159 schema:name Centre for Cancer Research and Cell Biology, Queen's University Belfast and Breast Surgery Department, Belfast City Hospital, Belfast, UK.
160 rdf:type schema:Organization
161 https://www.grid.ac/institutes/grid.4777.3 schema:alternateName Queen's University Belfast
162 schema:name Charles River Labs, 8-9 Spire Green Centre, Essex, Harlow, CM19 5TR, UK.
163 School of Pharmacy, Queen's University Belfast, Belfast, UK.
164 rdf:type schema:Organization
165 https://www.grid.ac/institutes/grid.4912.e schema:alternateName Royal College of Surgeons in Ireland
166 schema:name Department of Molecular and Cellular Therapeutics, Irish Centre for Vascular Biology, Royal College of Surgeons in Ireland, RCSI, Dublin, Ireland.
167 Department of Molecular and Cellular Therapeutics, Irish Centre for Vascular Biology, Royal College of Surgeons in Ireland, RCSI, Dublin, Ireland. tracyrobson@rcsi.ie.
168 School of Pharmacy, Queen's University Belfast, Belfast, UK.
169 School of Pharmacy, Queen's University Belfast, Belfast, UK. tracyrobson@rcsi.ie.
170 rdf:type schema:Organization
171 https://www.grid.ac/institutes/grid.5379.8 schema:alternateName University of Manchester
172 schema:name Manchester Breast Centre, Division of Cancer Sciences, University of Manchester, Oglesby Cancer Research Building, Manchester, UK.
173 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...